IL33 and leukemia: To test whether IL-33 treatment licenses DCs to efficiently prime leukemia-reactive CD8+ T cells, splenic CD11c+ cells purified from either PBS- or IL-33-treated C1498.SIY-bearing mice were cocultured with SIY-specific 2C CD8+ T cells for detection of IFN-γ production by ELISPOT.